Umeclidinium Ellipta Aerosol, Powder
Product Images NDC 66993-189

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Umeclidinium Ellipta (NDC 66993-189). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Umeclidinium Bromide Chemical Structure (Umeclidinium Ellipta Spl Graphic 01)

FDA Label Image

Figure 1 (Umeclidinium Ellipta Spl Graphic 02)

This description presents information about the population demographics in terms of gender, age groups, renal impairment, hepatic impairment, and metabolic enzyme inhibitors. It then provides recommendations for dose adjustments based on these factors, suggesting that there is no need for dose adjustments across different categories of the population.*

FDA Label Image

Figure 2 Day 1 (Umeclidinium Ellipta Spl Graphic 03)

This text provides information about the adjusted mean changes in Forced Expiratory Volume (FEV) in milliliters (mL) at different dosages and time points for various treatments such as Placebo, Umeclidinium, and Umedidinium. The values for FEV changes are given for different dosage levels (15.6 mcg, 31.25 mcg, 625 mcg, 125 mcg) of the treatments on Day 1 and at different time intervals (Time (h)).*

FDA Label Image

Figure 2 Day 7 (Umeclidinium Ellipta Spl Graphic 04)

FDA Label Image

Figure 3 Day 1 (Umeclidinium Ellipta Spl Graphic 05)

FDA Label Image

Figure 3 Day 168 (Umeclidinium Ellipta Spl Graphic 06)

FDA Label Image

Umeclidinium Ellipta Inhaler (Umeclidinium Ellipta Spl Graphic 07)

Desiccant Information.*

FDA Label Image

Figure A (Umeclidinium Ellipta Spl Graphic 08)

FDA Label Image

Figure B (Umeclidinium Ellipta Spl Graphic 09)

FDA Label Image

Figure C (Umeclidinium Ellipta Spl Graphic 10)

FDA Label Image

Figure D (Umeclidinium Ellipta Spl Graphic 11)

FDA Label Image

Figure E (Umeclidinium Ellipta Spl Graphic 12)

FDA Label Image

Figure F (Umeclidinium Ellipta Spl Graphic 13)

FDA Label Image

Figure G (Umeclidinium Ellipta Spl Graphic 14)

Keep the air vent unobstructed and do not block it with your fingers to ensure proper ventilation.*

FDA Label Image

Figure H (Umeclidinium Ellipta Spl Graphic 15)

FDA Label Image

Figure I (Umeclidinium Ellipta Spl Graphic 16)

FDA Label Image

Figure J (Umeclidinium Ellipta Spl Graphic 17)

FDA Label Image

Figure K (Umeclidinium Ellipta Spl Graphic 18)

FDA Label Image

Umeclidinium Ellipta 30 Dose Carton (Umeclidinium Ellipta Spl Graphic 19)

This is a description of Umeclidinium ELLIPTA Inhalation Powder by PRASCO. It is for oral inhalation only and each blister contains 62.5 mcg of umeclidinium along with magnesium stearate and lactose monohydrate. The product includes an ELLIPTA Inhaler with 1 foil strip of 30 blisters. The National Drug Code (NDC) is 66993-189-97. This medication is available by prescription only.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.